(Q41060480)

26 September 2017

1 reference

title

Diagnosis and drug therapy of prolactinoma (English)

1 reference

26 September 2017

E Ciccarelli

1

1 reference

26 September 2017

F Camanni

series ordinal

2

1 reference

26 September 2017

publication date

1 June 1996

1 reference

26 September 2017

1 reference

26 September 2017

volume

51

1 reference

26 September 2017

issue

6

1 reference

26 September 2017

page(s)

954-965

1 reference

Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.

26 September 2017

cites work

1 reference

12 December 2020

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

1 reference

12 December 2020

Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone

1 reference

12 December 2020

Double blind randomized study using oral or injectable bromocriptine in patients with hyperprolactinaemia

1 reference

12 December 2020

Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnancies

1 reference

12 December 2020

Dopamine agonists and pituitary tumor shrinkage

1 reference

12 December 2020

Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells

1 reference

12 December 2020

CV 205-502 treatment of hyperprolactinemia

1 reference

12 December 2020

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

12 December 2020

Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas

1 reference

12 December 2020

Magnetic resonance imaging in a routine clinical setting

1 reference

12 December 2020

Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study

1 reference

12 December 2020

1 reference

12 December 2020

Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.

1 reference

12 December 2020

Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland

1 reference

12 December 2020

Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR)

1 reference

12 December 2020

Dopamine, the dopamine D2 receptor and pituitary tumours

1 reference

12 December 2020

Multiple intracranial metastases from a prolactin secreting pituitary tumour

1 reference

12 December 2020

Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine

1 reference

12 December 2020

Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine

1 reference

12 December 2020

Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study.

1 reference

12 December 2020

Bromocriptine treatment of males with pituitary tumours, hyperprolactinaemia, and hypogonadism

1 reference

12 December 2020

Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas

1 reference

12 December 2020

Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy

1 reference

12 December 2020

Three dimensional CT reconstruction images for craniofacial surgical planning and evaluation

1 reference

12 December 2020

Spontaneous and induced pregnancies in hyperprolactinemic women

1 reference

12 December 2020

Pituitary tumors secreting growth hormone and prolactin

1 reference

12 December 2020

Histological classification of pituitary disease

1 reference

12 December 2020

Hyperprolactinemia: neuroendocrine and diagnostic aspects

1 reference

12 December 2020

Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma

1 reference

12 December 2020

Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma

1 reference

12 December 2020

Giant invasive prolactinoma: a case report and review of nine further cases.

1 reference

12 December 2020

Long-term Treatment of Galactorrhoea and Hypogonadism with Bromocriptine

1 reference

12 December 2020

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

1 reference

12 December 2020

In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide

1 reference

12 December 2020

High-resolution computed tomographic appearance of the intrasellar contents in women of childbearing age

1 reference

12 December 2020

Pituitary tumors and pregnancy

1 reference

12 December 2020

Necrotic changes in prolactinomas after long term administration of bromocriptine

1 reference

12 December 2020

Failure of bromocriptine to maintain reduction in size of a macroprolactinoma.

1 reference

12 December 2020

Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia

1 reference

12 December 2020

Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy

1 reference

12 December 2020

Primary treatment of macroprolactinomas with Parlodel LAR®

1 reference

12 December 2020

The Incidence of Complications During Pregnancy after Treatment of Hyperprolactinemia with Bromocriptine in Patients with Radiologically Evident Pituitary Tumors

1 reference

12 December 2020

A parallel study of the roentgen anatomy of the sella turcica and the histopathology of the pituitary gland in 205 autopsy specimens

1 reference

12 December 2020

Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series

1 reference

12 December 2020

Resistance to bromocriptine in prolactinomas

1 reference

12 December 2020

Pregnancy and the hyperprolactinemic woman

1 reference

12 December 2020

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation

1 reference

12 December 2020

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

12 December 2020

Management of prolactinomas

1 reference

12 December 2020

Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors

1 reference

12 December 2020

Nerve growth factor suppresses the transforming phenotype of human prolactinomas

1 reference

12 December 2020

Outcome of Pregnancy in Women with Pituitary Adenoma

1 reference

12 December 2020

Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.

1 reference

12 December 2020

Bromocriptine as prophylactic therapy in prolactinoma during pregnancy

1 reference

12 December 2020

Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia

1 reference

12 December 2020

Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors

1 reference

12 December 2020

10.2165/00003495-199651060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

26 September 2017

1023676015

0 references

1 reference